Interim results at 16 weeks were based on 50 adolescents and adults with skin types IV-VI.
who underwent 16 weeks of treatment with lebrikizumab, 68% achieved a 75% reduction in the Eczema Area and Severity Index , interim results from a novel phase 3b trial showed., a novel monoclonal antibody being developed by Eli Lilly and Co, binds with high affinity to interleukin –13, thereby blocking the downstream effects of IL-13 with high potency, one of the study investigators,, a dermatologist in Miami, Florida, said at the annual meeting of the American Academy of Dermatology.
Week 16 outcomes of interest were the EASI, the Investigator's Global Assessment of 0 or 1, the Pruritus Numerical Rating Scale , and PDCA-Derm, a scale developed by Eli Lilly and Co that was used to compare postinflammatory lesions to unaffected adjacent normal skin. All data for statistical analyses were summarized as observed.
After 16 weeks of treatment, 68% of patients achieved an EASI-75 response, whereas 46% achieved an EASI-90 response, Waibel reported at the meeting. In addition, 39% of patients achieved an IGA score of 0 or 1, 56% achieved a ≥ 4-point improvement on the Pruritus NRS, and 66% achieved a ≥ 3-point improvement on the Pruritus NRS. The PDCA-Derm score identified improvement in postinflammatory hyperpigmented lesions in 12 of 21 patients and improvement to normal skin tone in six of 21 patients.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Thousands of BCBSAZ patients out of network at Dignity Health, Aetna patients also at riskThousands are now out of network at Dignity, others at risk of losing coverage
Read more »
Which Factors Affect Stroke Recurrence After Chagas Disease?A recent study found that cardiovascular risk factors were prevalent among patients with Chagas disease.
Read more »
Watchful Waiting Less Expensive, as Effective as Physical Therapy for Frozen ShoulderA new study finds patients had similar outcomes with both treatment approaches but with a significant cost difference.
Read more »
Scientists Develop Simple and Cost-Effective Early Diabetes TestScience, Space and Technology News 2024
Read more »
A fast, effective, and long-lasting treatment for major depressive disorder.A new study has discovered a safer psychedelic that quickly treats major depression without producing hallucinations.
Read more »
Innovative Nanogel Shown Effective in Treating Spinal Cord InjuriesScience, Space and Technology News 2024
Read more »